CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

This pharma small-cap is rallying on Thursday morning!
Shamita Nadkarni
/ Categories: Trending, Mindshare

This pharma small-cap is rallying on Thursday morning!

The company posted robust Q1FY23 results.

The Indian stock market opened on a positive note and has sustained the gains. At 9.30 am, S&P BSE stands at 56,357.82, a gain of 541.5 points or 0.97 per cent while the stock of Novartis India rallied over 12 per cent.   

Headquartered in Basel (Switzerland), Novartis is a leading global medicines company. It is a science-based and patient-oriented healthcare company, which strives to be a global leader in the growing areas of healthcare.   

In India, the pharmaceutical business of Novartis India Limited is focussed on bone & pain, calcium portfolio, gynaecology & neurosciences while the generics business is focussed on gynaecology, anti-TB, and anti-infective.  

 On a standalone basis, the company posted the following results:   

For the quarter under review (Q1FY23), the net profit climbed 734.08 per cent to Rs 52.38 crore as against Rs 6.28 crore reported during the same quarter last year. Its sales witnessed a surge of 23.25 per cent to Rs 120.92 crore compared to the sales of Rs 98.11 crore reported in Q1FY22.     

In a positive market, the stock has skyrocketed by 13.44 per cent and the scrip is trading at Rs 739. The stock has a 52-week high of Rs 999 and a 52-week low of Rs 566.  

Previous Article Multibagger stock that delivered Rs 50.05 lakh on an investment of Rs 1 lakh, announces stock split
Next Article Managing Portfolio Overlapping Can Add Value!
Print
605 Rate this article:
4.5

1 comments on article "This pharma small-cap is rallying on Thursday morning!"

Avatar image

Imran Nazir

Yyy

Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR